Physician profile
Benjamin Witkoff
NPI 1700346509
$8,491.05
in general payments reported to CMS, 2019-2025
29 companies · $2,377 in 2025
The $2,377 reported for 2025 was more than what 91% of Mohs-Micrographic Surgery providers received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $23.67 · 2021: $858 · 2022: $1,377 · 2023: $1,984 · 2024: $1,871 · 2025: $2,377.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,232.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,231.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,809.94 | 2020-2025 | Skyrizi, Rinvoq |
| E.R. Squibb & Sons, L.L.C. | $1,031.38 | 2023-2024 | Sotyktu |
| Incyte Corporation | $567.97 | 2021-2025 | Opzelura, Opzelura |
| Novartis Pharmaceuticals Corporation | $493.29 | 2021-2025 | |
| Galderma Laboratories, L.P. | $398.94 | 2022-2025 | Aklief, Twyneo, Oracea |
| Regeneron Healthcare Solutions, INC. | $397.30 | 2022-2025 | Dupixent |
| Pfizer INC. | $392.96 | 2022-2025 | |
| Ucb, INC. | $390.90 | 2023-2025 | Bimzelx |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $368.42 | 2021-2025 | Arazlo, Jublia, Siliq |
| Amgen INC. | $367.32 | 2022-2024 | Otezla |
| Genzyme Corporation | $366.13 | 2022-2025 | |
| Sun Pharmaceutical Industries INC. | $360.47 | 2021-2025 | |
| Arcutis Biotherapeutics, INC. | $257.42 | 2024-2025 | Zoryve |
| Fresenius Kabi USA, LLC | $166.72 | 2023 | Idacio |
| Allergan, INC. | $162.50 | 2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $161.50 | 2023 | Tremfya |
| Janssen Scientific Affairs, LLC | $131.13 | 2025 | Tremfya |
| Convatec INC. | $118.70 | 2023 | |
| Dermavant Sciences, INC. | $113.82 | 2024 | Vtama |
| Lilly USA, LLC | $105.43 | 2022-2025 | Taltz, Ebglyss |
| Biofrontera INC. | $99.47 | 2021-2024 | Xepi, Bf-Rhodoled, Ameluz |
| Kerecis Limited | $39.55 | 2023-2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
| Lnhc, INC | $39.33 | 2025 | Zelsuvmi |
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.87 | 2023 | Spevigo |
| Leo Pharma INC. | $33.89 | 2024-2025 | Adbry |
| Verrica Pharmaceuticals INC. | $27.98 | 2024 | Ycanth |
| Organogenesis INC. | $20.93 | 2025 | Affinity |
| Mimedx Group, INC. | $19.84 | 2025 | |
| Organon LLC | $8.95 | 2025 | Vtama |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Benjamin Witkoff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.